WALL STREET JOURNAL

Written By Rob Cahill

Beyond GLP-1: Junevity Seeks Next-Generation Weight-Loss Medication

Biotechnology startup Junevity is joining the quest for novel obesity medications, doubling its seed financing to $20 million to advance a drug it hopes will help patients sustain long-term weight loss.

Read more here.

Rob Cahill
Next

AXIOS